Eskata

Manufacturer
Aclaris Therapeutics, Inc. | James Alexander Corp.
Effective date
2019-03-27
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 20:28:04

Label at a glance#

ProductEskata
Active ingredientHYDROGEN PEROXIDE
Label structure18 sections

Dosage and administration

ESKATA is to be administered by a health care provider. For topical use only. Not for oral, ophthalmic, or intravaginal use. Do not apply ESKATA topical solution to open or infected seborrheic keratoses. Prior to application of ESKATA, ensure the surface of seborrheic keratosis lesion is clear of oil and debris (an alcohol wipe can be used). During a single in-office treatment session, apply ESKATA to seborrheic k...

Storage and handling

ESKATA (hydrogen peroxide) topical solution, 40% (w/w) is a clear, colorless solution and is supplied in a unit dose package. The available carton packages are presented below: Dosage Strength Fill Volume Deliverable Volume Number of unit dose packages per carton NDC# 40% (w/w) 1.5 mL 0.7 mL 1 71180-001-01 3 71180-001-03 12 71180-001-12 2.2 mL 1.3 mL 1 71180-002-01 3 71180-002-03 12 71180-002-12 Store ESKATA at co...

Label contents#

Full prescribing information#

1. INDICATION AND USAGE

INDICATIONS & USAGE SECTION

ESKATA is indicated for the treatment of seborrheic keratoses that are raised.

2. DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Important Administration Information

SPL UNCLASSIFIED SECTION

ESKATA is to be administered by a health care provider.

For topical use only. Not for oral, ophthalmic, or intravaginal use.

Do not apply ESKATA topical solution to open or infected seborrheic keratoses.

Prior to application of ESKATA, ensure the surface of seborrheic keratosis lesion is clear of oil and debris (an alcohol wipe can be used).

During a single in-office treatment session, apply ESKATA to seborrheic keratosis lesions 4 times, approximately 1 minute apart. After one use, replace the cap and discard the unit dose applicator.

When treating seborrheic keratoses on the face, take appropriate actions to ensure that ESKATA will not come into contact with the eyes.

If the treated lesions have not completely cleared approximately 3 weeks after treatment, another treatment may be administered following the same procedure.

2.2 Dosage and Administration Instructions

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

Preparation of the ESKATA applicator

Wear nitrile or vinyl examination gloves during the activation of the ESKATA applicator and during the administration of the solution to the lesion(s).

The method for preparing the ESKATA applicator for use is illustrated below. While activating the applicator, hold it away from the patient. Do not remove the cap until after completion of Step 4 (below).

FigureFigure

FigureFigure

Step 1: Hold the ESKATA applicator so that the applicator cap is pointing upStep 2: Crush the ampule in the applicator by applying finger pressure to the diamond symbol on the applicator barrel

FigureFigure

FigureFigure

Step 3: Remove the sleeveStep 4: Holding the applicator with cap pointing up, tap the bottom of the applicator to separate the solution from the crushed ampule
SPL UNCLASSIFIED SECTION

Application of ESKATA topical solution

Following release of the solution from the ampule, remove the cap from the ESKATA applicator. Gently squeeze the applicator barrel to express the solution to the applicator tip. Using the applicator, apply the solution directly to the seborrheic keratosis in a circular motion. Apply enough solution to uniformly wet the lesion surface, including the edges without excess running or dripping.

Wait 1 minute and observe. Whitening of the lesion may occur.

Do not progress to subsequent applications if severe erythema/edema or pain occur. Apply again in the same manner 3 additional applications 1 minute apart.

Minimize the amount of drug that comes into contact with surrounding skin. If ESKATA does come into contact with surrounding skin, use an absorbent wipe to remove any excess solution (do not use paper towels or tissue).

3. DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

ESKATA topical solution is a clear, colorless solution containing 40% (w/w) hydrogen peroxide.

4. CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None.

5. WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Eye Disorders

SPL UNCLASSIFIED SECTION

Do not apply to the eyes or mucous membranes. Avoid treating seborrheic keratoses within the orbital rim. Direct contact with the eye can cause corneal injury (erosion, ulceration, perforation, and scarring), chemical conjunctivitis, eyelid edema, severe eye pain, or permanent eye injury, including blindness.

If accidental exposure occurs, flush with water for 15 to 30 minutes and initiate monitoring, and further evaluation as appropriate.

5.2 Local Skin Reactions

SPL UNCLASSIFIED SECTION

Skin reactions occurred in the treatment area after application of ESKATA. Severe local skin reactions included erosion, ulceration, vesiculation and scarring. [See Adverse Reactions (6.1)]. Do not initiate a second treatment course with ESKATA until the skin has recovered from any reaction caused by the previous treatment.

6. ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 Clinical Trials Experience

SPL UNCLASSIFIED SECTION

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to ESKATA or vehicle in a total of 937 subjects with seborrheic keratoses that are raised. Overall, 42% of the subjects were male and 58% were female. Ninety-eight (98) percent of the subjects were Caucasian and the mean age was 68.7 years.

At each visit, local skin reactions were graded for severity to determine the maximum severity after treatment. Table 1 presents the percentage of subjects with the local adverse reactions by the most severe grade reported during the course of the trials.

Table 1. Percentage of Subjects with Local Skin Reactions by Severity
ESKATA
N=467
Vehicle
N=470
MildModerateSevereTotalMildModerateSevereTotal
Erythema13671999295<134
Stinging3449159791<110
Edema284815916106
Scaling4936590285133
Crusting3438881135119
Pruritus341855871<18
Hyperpigmentation327<1391<101
Vesicles213124<100<1
Hypopigmentation163<1191<101
Erosion122115<1001
Ulceration62<191102
Atrophy40040000
Scarring3<1<130000

Common local skin reactions observed 10 minutes after treatment include: erythema (98%), stinging (93%), edema (85%), pruritus (32%), and vesiculation (18%).

Common local skin reactions observed 1 week after treatment are scaling (72%), erythema (66%), crusting (67%), pruritus (18%), erosion (9%), and ulceration (4%).

Common local skin reactions observed 15 weeks after the initial treatment are erythema (21%), hyperpigmentation (18%), scaling (16%), crusting (12%), and hypopigmentation (7%).

Less common adverse reactions occurring in ≥ 0.5% of subjects treated with ESKATA include eyelid edema (0.6%) and herpes zoster (0.6%).

6.2 Postmarketing Experience

SPL UNCLASSIFIED SECTION

The following adverse reactions have been identified during post-approval use of ESKATA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and subcutaneous tissues disorders: crepitus

8. USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

SPL UNCLASSIFIED SECTION

Risk Summary

Hydrogen peroxide is not absorbed systemically following topical administration, and maternal use is not expected to result in fetal exposure to the drug.

8.2 Lactation

LACTATION SECTION

SPL UNCLASSIFIED SECTION

Risk Summary

Hydrogen peroxide is not absorbed systemically by the mother following topical administration, and breastfeeding is not expected to result in exposure of the child to hydrogen peroxide.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Seborrheic keratosis is not seen in the pediatric population.

8.5 Geriatric Use

GERIATRIC USE SECTION

Of the 841 subjects treated with ESKATA in the clinical trials, 70% were 65 years of age and older and 26% were 75 years of age and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

10. OVERDOSE

OVERDOSAGE SECTION

Topical overdosing of ESKATA could result in an increased incidence and severity of local skin reactions.

11. DESCRIPTION

DESCRIPTION SECTION

ESKATA (hydrogen peroxide) topical solution, 40% (w/w) is a clear, colorless solution for topical administration, which contains the active ingredient, hydrogen peroxide.

The chemical name of hydrogen peroxide is dihydrogen dioxide.

The molecular formula of hydrogen peroxide is H2O2 and the molecular weight is 34.01. Hydrogen peroxide is represented by the following structural formula:

Chemical Structure
Chemical Structure

ESKATA contains 40% (w/w) hydrogen peroxide in an aqueous solution of isopropyl alcohol and water.

12. CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

The mechanism of action for ESKATA for the treatment of seborrheic keratosis is unknown.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

The pharmacodynamics of ESKATA in the treatment of seborrheic keratosis are unknown.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Following application of ESKATA in patients with seborrheic keratosis lesions, hydrogen peroxide rapidly dissociates into water and reactive oxygen species. Indirect assessment of reactive oxygen species in patients with seborrheic keratosis lesions did not demonstrate any systemic absorption of hydrogen peroxide.

13. NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies have not been performed to evaluate the carcinogenic potential of ESKATA or hydrogen peroxide.

Hydrogen peroxide has been found to exhibit positive results in in vitro tests for genotoxicity, but has not exhibited positive results in in vivo tests for genotoxicity, presumably due to the rapid metabolism of hydrogen peroxide.

The effects of hydrogen peroxide on fertility have not been evaluated. Hydrogen peroxide has been associated with effects on sperm function and elevated testicular hydrogen peroxide concentration has been implicated in male infertility, although in vivo, no effect of hydrogen peroxide on sperm function has been demonstrated.

14. CLINICAL STUDIES

CLINICAL STUDIES SECTION

In two double-blind, vehicle-controlled clinical trials, 937 subjects with 4 clinically typical seborrheic keratoses that are raised on the face, trunk, or extremities were randomized to treatment with either ESKATA or vehicle. Subjects ranged from 42 to 91 years of age (mean 68.7 years), 58% percent were female, and 98% were Caucasian. A total of 925 subjects completed the trials. Each lesion was treated with 4 applications, at baseline and again at Day 22, if needed, and subjects were followed through Day 106.

Efficacy was assessed at Day 106. Success rate was defined as the proportion of subjects achieving "clear" on the Physician's Lesion Assessment Scale for all 4 treated lesions. Efficacy was also assessed for the proportion of subjects achieving "clear" on the Physician's Lesion Assessment Scale for at least 3 of 4 lesions. Table 3 presents the efficacy results for the two clinical trials.

Table 2. Percentage of Subjects Achieving Clearance of Target Lesions at Day 106 in Study 1 and Study 2
Study 1Study 2
ESKATA
N=223
Vehicle
N=227
ESKATA
N=244
Vehicle
N=243
All 4 lesions "Clear"4%0%8%0%
At least 3 of 4 lesions "Clear"13%0%23%0%

16. HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

ESKATA (hydrogen peroxide) topical solution, 40% (w/w) is a clear, colorless solution and is supplied in a unit dose package. The available carton packages are presented below:

Dosage StrengthFill VolumeDeliverable VolumeNumber of unit dose packages per cartonNDC#
40% (w/w)1.5 mL0.7 mL171180-001-01
371180-001-03
1271180-001-12
2.2 mL1.3 mL171180-002-01
371180-002-03
1271180-002-12

STORAGE AND HANDLING SECTION

Store ESKATA at controlled room temperature of 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59° F and 86° F).

17. PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

SPL UNCLASSIFIED SECTION

Ophthalmic Adverse Reactions

Inform patients that severe eye injury can occur with ESKATA application. Advise patients to inform the healthcare provider immediately if ESKATA runs into eyes, mouth, or nose during administration [see Warnings and Precautions (5.1)].

SPL UNCLASSIFIED SECTION

Local Skin Reactions

Inform patients that treatment with ESKATA may lead to local skin reactions [see Warnings and Precautions (5.2)].

SPL UNCLASSIFIED SECTION

Manufactured & Packaged by:
James Alexander Corp.
845 Route 94
Blairstown, NJ 07825
United States

For:
Aclaris Therapeutics, Inc.
640 Lee Road, Suite 200
Wayne, PA 19087
United States

US Patent Numbers: US 7,381,427, US 9,675,639, US 9,980,983 and US 10,098,910

SPL PATIENT PACKAGE INSERT SECTION

This Patient Information has been approved by the U.S. Food and Drug AdministrationIssued: December 2017
Patient Information
ESKATA® (es-KAH-tah)
(hydrogen peroxide), topical solution
IMPORTANT: ESKATA topical solution is for use as an in-office treatment. ESKATA is applied by your healthcare provider and is not for use at home.
What is ESKATA ?
ESKATA is a prescription medicine used to treat seborrheic keratoses that are raised.
Before treatment with ESKATA, tell your healthcare provider about all of your medical conditions, including if you:
  • are being treated or have had treatments for seborrheic keratosis
  • have other skin problems
  • are pregnant or plan to become pregnant.
  • are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
How should I receive ESKATA ?
  • Your healthcare provider will apply ESKATA to your seborrheic keratosis lesions.
  • Your healthcare provider may apply ESKATA again, about 3 weeks after your treatment if your treated lesions are not completely gone.
What are the possible side effects with ESKATA?
ESKATA can cause serious side effects, including:
  • Eye problems. Eye problems can happen if ESKATA gets into your eyes, including:
  • ulcers or small holes in your eyes
  • scarring
  • redness
  • irritation
  • eyelid swelling
  • severe eye pain
  • permanent eye injury, including blindness
If ESKATA accidentally gets into your eyes, your healthcare provider will tell you to flush them well with water for 15 to 30 minutes. Your healthcare provider may send you to another healthcare care provider if needed.
  • Local skin reactions. Skin reactions have happened in and around the treatment area after application of ESKATA. Severe skin reactions can include: breakdown of the outer layer of the skin (erosion), ulcers, blisters and scarring. Tell your healthcare provider if you have any skin reactions during treatment with ESKATA.
The most common side effects of ESKATA include: itching, stinging, crusting, swelling, redness and scaling.
Your healthcare provider will not apply another treatment of ESKATA if your treated area is still irritated from the previous treatment.
Tell your healthcare provider right away if ESKATA gets into your eyes, mouth or nose during application.
These are not all of the possible side effects of ESKATA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of ESKATA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.
What are the ingredients in ESKATA?
Active ingredient: hydrogen peroxide
Inactive ingredients: isopropyl alcohol and water.
Manufactured & Packaged by: James Alexander Corp., 845 Route 94, Blairstown, NJ 07825 United States
For: Aclaris Therapeutics, Inc., 640 Lee Rd, Suite 200, Wayne, PA 19087 United States
US Patent Number: US 7,381,427, US 9,675,639, US 9,980,983 and US 10,098,910

PRINCIPAL DISPLAY PANEL - 0.7 mL Applicator Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC: 71180-001-03

3 Units
Rx Only
Store at 20-25°C

ACLARIS
THERAPEUTICS

eskata™
(hydrogen peroxide) topical solution, 40% (w/w)

Single use applicator/0.7 mL. For Topical Use Only.

Marketed by
Aclaris Therapeutics, Inc.
Malvern, PA 19355
www.aclaristx.com

US Patent 7,381,427

PRINCIPAL DISPLAY PANEL - 0.7 mL Applicator Carton
PRINCIPAL DISPLAY PANEL - 0.7 mL Applicator Carton

PRINCIPAL DISPLAY PANEL - 1.3 mL Applicator Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC: 71180-002-03

3 Units
Rx Only
Store at 20-25°C

ACLARIS
THERAPEUTICS

eskata™
(hydrogen peroxide) topical solution, 40% (w/w)

Single use applicator/1.3 mL. For Topical Use Only.

Marketed by
Aclaris Therapeutics, Inc.
Malvern, PA 19355
www.aclaristx.com

US Patent 7,381,427

PRINCIPAL DISPLAY PANEL - 1.3 mL Applicator Carton
PRINCIPAL DISPLAY PANEL - 1.3 mL Applicator Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1993067Eskata 40 % Topical SolutionPSN4
251182hydrogen peroxide 40 % Topical SolutionPSN4
1993067hydrogen peroxide 400 MG/ML Topical Solution [Eskata]SBD4
251182hydrogen peroxide 400 MG/ML Topical SolutionSCD4
1993067Eskata 40 % Topical SolutionSY4
1993067Eskata 400 MG/ML Topical SolutionSY4

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
5eb9f24b-9328-475e-af0a-18021935eb6aProduct name120180220

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
71180-001-012021-01-29C16284748780-1ba0f9c33-1104-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use ESKATA ® safely and effectively. See full prescribing information for ESKATA ® . ESKATA ® (hydrogen peroxide) topical solution Initial U.S. Approval: 2017
71180-001-032021-01-29C16284748780-1ba0f9c33-1104-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use ESKATA ® safely and effectively. See full prescribing information for ESKATA ® . ESKATA ® (hydrogen peroxide) topical solution Initial U.S. Approval: 2017
71180-001-122021-01-29C16284748780-1ba0f9c33-1104-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use ESKATA ® safely and effectively. See full prescribing information for ESKATA ® . ESKATA ® (hydrogen peroxide) topical solution Initial U.S. Approval: 2017
71180-002-012021-01-29C16284748780-1ba0f9c33-1104-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use ESKATA ® safely and effectively. See full prescribing information for ESKATA ® . ESKATA ® (hydrogen peroxide) topical solution Initial U.S. Approval: 2017
71180-002-032021-01-29C16284748780-1ba0f9c33-1104-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use ESKATA ® safely and effectively. See full prescribing information for ESKATA ® . ESKATA ® (hydrogen peroxide) topical solution Initial U.S. Approval: 2017
71180-002-122021-01-29C16284748780-1ba0f9c33-1104-a910-e053-dadaa90a0b85These highlights do not include all the information needed to use ESKATA ® safely and effectively. See full prescribing information for ESKATA ® . ESKATA ® (hydrogen peroxide) topical solution Initial U.S. Approval: 2017

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
71180-001-01Eskata280 mg in 1 APPLICATORSOLUTION2804
71180-001-01Eskata1 in 1 CARTONSOLUTION14
71180-001-03Eskata3 in 1 CARTONSOLUTION34
71180-001-03Eskata280 mg in 1 APPLICATORSOLUTION2804
71180-001-12Eskata12 in 1 CARTONSOLUTION124
71180-001-12Eskata280 mg in 1 APPLICATORSOLUTION2804
71180-002-01Eskata1 in 1 CARTONSOLUTION14
71180-002-01Eskata520 mg in 1 APPLICATORSOLUTION5204
71180-002-03Eskata520 mg in 1 APPLICATORSOLUTION5204
71180-002-03Eskata3 in 1 CARTONSOLUTION34
71180-002-12Eskata12 in 1 CARTONSOLUTION124
71180-002-12Eskata520 mg in 1 APPLICATORSOLUTION5204

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
71180-001ESKATA (HYDROGEN PEROXIDE) SOLUTION [ACLARIS THERAPEUTICS, INC.]4Legacy NDC, 6 package rows20190328_52f4cc49-6553-426f-9778-0bd34e31b942.zip
71180-002ESKATA (HYDROGEN PEROXIDE) SOLUTION [ACLARIS THERAPEUTICS, INC.]4Legacy NDC, 6 package rows20190328_52f4cc49-6553-426f-9778-0bd34e31b942.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
71180-001-12EA - Each71180-00133c5961f-8e3b-46f3-a89a-2a6722b78dd812018-07-03

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71180-00171180-001-01, 71180-001-03, 71180-001-12
71180-00271180-002-01, 71180-002-03, 71180-002-12

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N209305-001ESKATAHYDROGEN PEROXIDE40%SOLUTION / TOPICALRLD2017-12-14

Orange Book patents#

Current patent rows page 1 of 1 · 5 matching rows.

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N209305-001100989102035-04-21U-2205Drug product2018-10-25
N209305-001104931032035-04-21Drug product2020-01-21
N209305-001107297202035-04-21Drug product2020-08-11
N209305-00199809832035-04-21U-22052018-06-18
N209305-00196756392035-07-04U-2205Drug product2018-01-03

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14d4dbc9d85df4…
2026-10-15 13:18:302026-09N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14c2088c7a36db…
2026-09-14 22:38:342026-08N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-1484e616aacf4f…
2026-08-18 06:07:402026-07N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-1431067a03dcf5…
2025-08-23 18:47 UTC2025-08N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-146a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-1403ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-142680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-145bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-1479d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-141e350fbaab3a…
2024-05-31 18:47 UTC2024-05N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-148072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-145c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-145d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-144b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-1474a2ff9319b5…
2022-03-09 01:35 UTC2022-03N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-1487673890dc5c…
2021-03-12 10:30 UTC2021-03N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-145aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-148869cabd3fbd…
2020-11-12 02:37 UTC2020-11N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14c0c555d07b60…
2019-12-14 00:12 UTC2019-12N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-143f01610625f2…
2019-09-15 20:21 UTC2019-09N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14b00525d2431f…
2019-07-19 19:46 UTC2019-07N209305-001ESKATA40%SOLUTION / TOPICALRLD, RS2017-12-14ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-146a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-141c564ffb4f44…
2023-12-20 04:57 UTC2023-12N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-149b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-143f0d92c62455…
2023-05-13 08:27 UTC2023-05N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-14053a50430f4f…
2023-01-26 05:58 UTC2023-01N209305-001ESKATA40%SOLUTION / TOPICALRLD2017-12-143bdfa0b2c4d7…

Observed Orange Book patent history#

Patent history page 1 of 6 · 235 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2026-11-14 07:37:172026-10N209305-001100989102035-04-21U-2205Drug product2018-10-25d4dbc9d85df4…
2026-11-14 07:37:172026-10N209305-001104931032035-04-21Drug product2020-01-21d4dbc9d85df4…
2026-11-14 07:37:172026-10N209305-001107297202035-04-21Drug product2020-08-11d4dbc9d85df4…
2026-11-14 07:37:172026-10N209305-00199809832035-04-21U-22052018-06-18d4dbc9d85df4…
2026-11-14 07:37:172026-10N209305-00196756392035-07-04U-2205Drug product2018-01-03d4dbc9d85df4…
2026-10-15 13:18:302026-09N209305-001100989102035-04-21U-2205Drug product2018-10-25c2088c7a36db…
2026-10-15 13:18:302026-09N209305-001104931032035-04-21Drug product2020-01-21c2088c7a36db…
2026-10-15 13:18:302026-09N209305-001107297202035-04-21Drug product2020-08-11c2088c7a36db…
2026-10-15 13:18:302026-09N209305-00199809832035-04-21U-22052018-06-18c2088c7a36db…
2026-10-15 13:18:302026-09N209305-00196756392035-07-04U-2205Drug product2018-01-03c2088c7a36db…
2026-09-14 22:38:342026-08N209305-001100989102035-04-21U-2205Drug product2018-10-2584e616aacf4f…
2026-09-14 22:38:342026-08N209305-001104931032035-04-21Drug product2020-01-2184e616aacf4f…
2026-09-14 22:38:342026-08N209305-001107297202035-04-21Drug product2020-08-1184e616aacf4f…
2026-09-14 22:38:342026-08N209305-00199809832035-04-21U-22052018-06-1884e616aacf4f…
2026-09-14 22:38:342026-08N209305-00196756392035-07-04U-2205Drug product2018-01-0384e616aacf4f…
2026-08-18 06:07:402026-07N209305-001100989102035-04-21U-2205Drug product2018-10-25caaa826d4ba7…
2026-08-18 06:07:402026-07N209305-001104931032035-04-21Drug product2020-01-21caaa826d4ba7…
2026-08-18 06:07:402026-07N209305-001107297202035-04-21Drug product2020-08-11caaa826d4ba7…
2026-08-18 06:07:402026-07N209305-00199809832035-04-21U-22052018-06-18caaa826d4ba7…
2026-08-18 06:07:402026-07N209305-00196756392035-07-04U-2205Drug product2018-01-03caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N209305-001100989102035-04-21U-2205Drug product2018-10-25011fe1cb6892…
2026-02-19 14:30 UTC2026-02N209305-001104931032035-04-21Drug product2020-01-21011fe1cb6892…
2026-02-19 14:30 UTC2026-02N209305-001107297202035-04-21Drug product2020-08-11011fe1cb6892…
2026-02-19 14:30 UTC2026-02N209305-00199809832035-04-21U-22052018-06-18011fe1cb6892…
2026-02-19 14:30 UTC2026-02N209305-00196756392035-07-04U-2205Drug product2018-01-03011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N209305-001100989102035-04-21U-2205Drug product2018-10-2531067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N209305-001104931032035-04-21Drug product2020-01-2131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N209305-001107297202035-04-21Drug product2020-08-1131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N209305-00199809832035-04-21U-22052018-06-1831067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N209305-00196756392035-07-04U-2205Drug product2018-01-0331067a03dcf5…
2025-08-23 18:47 UTC2025-08N209305-001100989102035-04-21U-2205Drug product2018-10-256a471c1ec25d…
2025-08-23 18:47 UTC2025-08N209305-001104931032035-04-21Drug product2020-01-216a471c1ec25d…
2025-08-23 18:47 UTC2025-08N209305-001107297202035-04-21Drug product2020-08-116a471c1ec25d…
2025-08-23 18:47 UTC2025-08N209305-00199809832035-04-21U-22052018-06-186a471c1ec25d…
2025-08-23 18:47 UTC2025-08N209305-00196756392035-07-04U-2205Drug product2018-01-036a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N209305-001100989102035-04-21U-2205Drug product2018-10-25fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N209305-001104931032035-04-21Drug product2020-01-21fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N209305-001107297202035-04-21Drug product2020-08-11fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N209305-00199809832035-04-21U-22052018-06-18fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N209305-00196756392035-07-04U-2205Drug product2018-01-03fd3edfee7708…

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
CapturedEditionApplication-productExclusivity codeExpirationSource SHA-256
2019-12-13 00:20 UTC2019-12N209305-001NP2020-12-1474a2ff9319b5…
2020-12-22 03:56 UTC2020-12N209305-001NP2020-12-148869cabd3fbd…
2020-11-12 02:37 UTC2020-11N209305-001NP2020-12-14c0c555d07b60…
2019-12-14 00:12 UTC2019-12N209305-001NP2020-12-143f01610625f2…
2019-09-15 20:21 UTC2019-09N209305-001NP2020-12-14b00525d2431f…
2019-07-19 19:46 UTC2019-07N209305-001NP2020-12-14ea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
03a97001-7d04-427a-9e50-c3bef5db5dc952f4cc49-6553-426f-9778-0bd34e31b9422019-03-27Warnings, Adverse reactionsExact identifier
spl id: 03a97001-7d04-427a-9e50-c3bef5db5dc9
spl set id: 52f4cc49-6553-426f-9778-0bd34e31b942

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.